Baker & McKenzie in Australia
Learn about us Globally »
English (Change Language)
Baker & McKenzie in Australia
Learn about us Globally »
Combining the knowledge of local laws and cultures with a global reach is just one of the ways Baker & McKenzie separates itself from other firms. Our genuinely global perspective allows us to operate without boundaries around the world, in every jurisdiction that is important to your business.

Select a region or country to learn about on-the-ground resources immersed in the local culture or Learn about us Globally to view our talent and services worldwide.

When content is available in multiple languages, please select your preference on the right.

Pharmaceuticals & Healthcare in Australia

Baker & McKenzie's Australia Pharmaceuticals and Health Care lawyers work with market leaders including Pfizer, Schering-Plough, Hospira, Inc, Cardinal Health, CR Bard, Boston Scientific, Genetic Technologies, Victor Chang Cardiac Research, IBA Health, Sonic Healthcare and Bayer Australia to deliver a range of legal advice and representation.

Drawing on vast experience and industry experience, the group comprises lawyers with excellence in corporate and commercial, competition and consumer law, disputes (including product liability), employment, environment, intellectual property, regulatory, compliance and tax advice.

The Australia group is part of Baker & McKenzie's Global Pharmaceuticals & Health Care platform, which helps to facilitate sharing knowledge and skills to ensure that clients benefit from global experience.

Highlights of our experience includes, advising:

  • A large health industry company of its arrangements with healthcare practitioners and other third-parties in at least 21 countries, including, conducting a global compliance and operational review;
  • Hospira, Inc., on the AUD2.7 billion takeover of Mayne Pharma Limited by way of scheme of arrangement;
  • Sonic Healthcare on the AUD400 million acquisition of Clinical Pathology Laboratories;
  • IBA Health on the cross-border acquisition of iSoft Group plc and associated fundraising initiatives including an AUD165 million renounceable rights issue to shareholders, AUD300 million placement to institution investors, and debt raising;
  • Bovigen, a US-based acquirer of gene marker technology and businesses, in a multi-jurisdictional transaction involving the negotiation of a series of complex licences with the CSIRO, various Cooperative Research Centres, industry organizations and universities, and reciprocal technology transfer, support services and research and development agreements. Pfizer subsequently acquired both Bovigen and Catapult Genetics, the other party to the transaction;
  • Victor Chang Cardiac Research Institute on the commercialisation, management and protection of its intellectual property and on a range of agreements including research, material transfers, clinical trials, as well as testing and research on sample products at the pre-clinical trial stage;
  • A global pharmaceutical company in proceedings brought in the Federal Court against our client and other companies arising out of the global vitamins cartel and also defending the subsequent civil class action.

Our lawyers hold key positions in industry associations and health committees, including AusBiotech and AmCham.

Our practices worldwide were highly recommended in the Life Sciences Industry and Regulatory Super League for 2008 featured in the PLC Cross-border Quarterly (April-June 2008): Life Sciences Review.

Effective 18 January 2014, Turkey implements more severe sanctions and penalties on the manufacture, marketing and sale of counterfeit and fake medicines and for violation of promotion rules.
Doing Business in the Netherlands 2014 provides easy access to information about the legal and fiscal environment of the Netherlands and the rules and regulations that companies must consider when doing business here. The booklet describes the main implications for customs, distribution and sales, considers the legal forms of companies, tax rules and regulations and labor law. These are all important aspects to consider when establishing a profitable firm.
The question whether a license agreement will survive the insolvency of the licensor is still one of the hottest topics in German licensing law. It also has significant impact on M&A processes in particular if the target company’s business and turnover is dependent on the continued use of certain in-licensed compounds.
Read More
Read More
Read More
For further information, please contact:
+ 61 2 8922 5522
+ 61 2 8922 5342
Search Globally     Search Australia

Search Globally     Search Australia
Alphabetical by Last Name
Every day our more than 4,000 lawyers, economists, tax advisors and other professionals share insights and best practices across borders and practices. We speak more than 75 languages and represent more than 55 nationalities, and the close relationships among our people fosters the trust needed to develop and deliver world-class solutions to multinational clients.

We share an uncompromising commitment to excellence, which explains why more of our lawyers are included as leading lawyers in the Chambers Global Guide to the World’s Best Lawyers than any other Global 20 law firm.

To find a Baker & McKenzie lawyer or other professional, enter a search parameter to the left.
Passionately global
We are passionately global — it's in our DNA.

We started with a vision of going global and were in eight countries before our 10th anniversary. Today we have 77 offices in 47 countries -- including the emerging markets so important to the growth of your business.
We offer world-class career opportunities around the globe, while our entrepreneurial culture makes Baker & McKenzie a unique place to develop professionally.

Explore us Locally by selecting a region, country or office below, or select Submit to view our site Globally.